|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
CHEMICON International, Inc. (SERO) Licenses Its Patented Amplifluor Technology For Cancer Diagnostics To OncoMethylome Sciences S.A.
10/19/2005 5:13:10 PM
ATLANTA--(BUSINESS WIRE)--March 30, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary and OncoMethylome Sciences S.A.("OMS") have entered into an agreement pursuant to which OMS has licensed Chemicon's patented fluorescent detection technology, Amplifluor(R), for the clinical development of diagnostic assays detecting DNA methylation patterns.
DNA methylation is one of the primary biological mechanisms that determine gene expression. Thus, DNA methylation is an essential control mechanism for the normal development and cellular functioning of organisms. Abnormal DNA methylation, or hyper-methylation of DNA, incorrectly switches off critical genes, such as tumor suppressor genes or DNA repair genes, allowing cancers to develop and progress. DNA methylation patterns act as specific markers for disease and measuring the differences in DNA methylation patterns between healthy and diseased states provides a reliable and sensitive method for identifying disease and disease progression.
|
|
|
|
|
|
|
|
|
|
|